BioNTech

OverviewSuggest Edit

BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
TypePublic
Founded2008
HQMainz, DE
Websitebiontech.de
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2020)1,941(+50%)
Job Openings533
Revenue (FY, 2020)€482.3 M(+345%)
Share Price (May 2022)€142.6
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BioNTech

Sean Marett

Sean Marett

Chief Business and Chief Commercial Officer
Ugur Sahin

Ugur Sahin

Chief Executive Officer
Ryan Richardson

Ryan Richardson

Chief Strategy Officer
Ozlem Tureci

Ozlem Tureci

Chief Medical Officer
Zach Taylor

Zach Taylor

VP of Corporate Development and Strategy
Richard Gaynor

Richard Gaynor

President of BioNTech US and Chief of R&D
Show more

BioNTech Office Locations

BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
Show all (8)

BioNTech Financials and Metrics

BioNTech Revenue

BioNTech's revenue was reported to be €482.33 m in FY, 2020
EUR

Revenue (FY, 2020)

482.3m

Gross profit (FY, 2020)

677.0m

Net income (FY, 2020)

15.2m

EBITDA (FY, 2020)

(43.7m)

EBIT (FY, 2020)

(82.4m)

Market capitalization (25-May-2022)

37.3b

Closing stock price (25-May-2022)

142.6

Cash (31-Dec-2020)

1.2b

EV

36.3b
BioNTech's current market capitalization is €37.3 b.
Annual
EURFY, 2019FY, 2020

Revenue

108.6m482.3m

Cost of goods sold

(15.9m)(55.9m)

Gross profit

95.5m677.0m

R&D expense

(198.9m)(614.8m)
Quarterly
EURQ1, 2020Q2, 2020Q3, 2020

Revenue

27.7m41.8m67.5m

Cost of goods sold

(5.8m)(5.7m)(6.8m)

Gross profit

22.2m36.9m69.4m

R&D expense

(65.1m)(95.2m)(227.7m)
Annual
EURFY, 2019FY, 2020

Cash

519.1m1.2b

Accounts Receivable

11.9m165.5m

Prepaid Expenses

756.0k898.0k

Inventories

12.1m64.1m
Quarterly
EURQ1, 2020Q2, 2020Q3, 2020

Cash

451.6m573.0m990.5m

Accounts Receivable

10.3m7.7m7.2m

Prepaid Expenses

980.0k1.0m724.0k

Inventories

9.6m8.6m12.4m
Annual
EURFY, 2019FY, 2020

Net Income

(179.2m)15.2m

Depreciation and Amortization

33.9m38.7m

Inventories

(5.8m)(49.8m)
Quarterly
EURQ1, 2020Q2, 2020Q3, 2020

Net Income

(53.4m)(143.9m)(351.7m)

Depreciation and Amortization

8.6m17.4m26.2m

Inventories

2.2m3.2m(508.0k)
EURFY, 2019

EV/EBITDA

-48.9 x

EV/EBIT

-39.8 x

EV/CFO

-36.4 x

Revenue/Employee

90.5k
Show all financial metrics

BioNTech Operating Metrics

Oct, 2019

Patents (US)

45

Phase I Trials Products

8

Phase II Trials Products

1

Pre-Clinical Phase Products

11

BioNTech Acquisitions / Subsidiaries

Company NameDateDeal Size
Apta IT
BioNTech Austria Beteiligungen GmbH
BioNTech Business Services
BioNTech Cell & Gene Therapies
BioNTech Diagnostics
BioNTech Innovative Manufacturing Services
BioNTech Protein Therapeutics
BioNTech Real Estate GmbH & Co. KG
BioNTech Real Estate Verwaltungs
BioNTech Research and Development
Show more

BioNTech Revenue Breakdown

Embed Graph

BioNTech revenue breakdown by business segment: 30.8% from CLINICAL, 44.9% from MANUFACTURING, 21.6% from PRODUCT SALES & EXTERNAL SERVICES and 2.6% from Other

BioNTech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

BioNTech Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

BioNTech Online and Social Media Presence

Embed Graph

BioNTech News and Updates

Coronavirus tally: FDA advisory panel to meet June 15 to discuss Pfizer, BioNTech and Moderna vaccines for children aged 6 months to 4 years

The Food and Drug Administration said Monday an advisory panel would meet June 15 to discuss use of the vaccines developed by Pfizer Inc. and German partner BioNTech SE as well as the one developed by Moderna Inc. in children aged 6 months to four years old. The announcement came after Pfizer and…

Pfizer, BioNTech COVID-19 vaccine for children aged 6 months to 5 years meets EUA criteria

Shares of Pfizer Inc. rose 0.3% and BioNTech SE rallied 1.3% in premarket trading, after the drug makers said three doses of it COVID-19 vaccine for children aged six months to five years "met all immunobridging criteria" required for Emergency Use Authorization by the U.S. Food and Drug Administr…

BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter

BioNTech SE and Pfizer Inc. said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requ…

BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children

BioNTech SE and Pfizer Inc. said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults. The companies said data from a Phase 2/3 clinical trial yielded …

Pfizer and BioNTech say data shows high immune response for COVID booster in children aged 5 to 11

Pfizer Inc. and German partner BioNTech SE said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron var…

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

NEW YORK and MAINZ, Germany, April 14, 2022 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech CO…
Show more

BioNTech Blogs

home-rebrush

home-rebrush admin Tue, 03/30/2021 - 07:37

Overview COVID-19

Overview COVID-19 admin Wed, 12/02/2020 - 00:45

HCP 4 Technology Platforms for COVID-19 vaccines

HCP 4 Technology Platforms for COVID-19 vaccines admin Sun, 11/29/2020 - 20:09

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates admin Sun, 11/29/2020 - 20:09

HCP 1 The Virus Sars Cov 2

HCP 1 The Virus Sars Cov 2 admin Sun, 11/29/2020 - 20:09

HCP 2 The Disease COVID-19

HCP 2 The Disease COVID-19 admin Sun, 11/29/2020 - 20:09
Show more

BioNTech Frequently Asked Questions

  • When was BioNTech founded?

    BioNTech was founded in 2008.

  • Who are BioNTech key executives?

    BioNTech's key executives are Sean Marett, Ugur Sahin and Ryan Richardson.

  • How many employees does BioNTech have?

    BioNTech has 1,941 employees.

  • What is BioNTech revenue?

    Latest BioNTech annual revenue is €482.3 m.

  • What is BioNTech revenue per employee?

    Latest BioNTech revenue per employee is €248.5 k.

  • Who are BioNTech competitors?

    Competitors of BioNTech include APEIRON Biologics, Ohm Oncology and Kite Pharma.

  • Where is BioNTech headquarters?

    BioNTech headquarters is located at An der Goldgrube 12, Mainz.

  • Where are BioNTech offices?

    BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.

  • How many offices does BioNTech have?

    BioNTech has 8 offices.